This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside
The company reported that Tyvaso demonstrated superiority over the placebo in terms of the change in absolute forced vital capacity, increasing by 95.6 mL from baseline to week 52 in patients with idiopathic pulmonary fibrosis in the trial.